We are live on ! Find out more
PHK

Point72 Hong Kong Portfolio holdings

AUM $2.18B
1-Year Est. Return 89.02%
This Fund
S&P 500
This Quarter Est. Return
+1.65%
1 Year Est. Return
+89.02%
3 Year Est. Return
+396.1%
5 Year Est. Return
+490.26%
10 Year Est. Return
+2,256.67%
AUM
$365M
AUM Growth
+$111M
Cap. Flow
+$103M
Cap. Flow %
28.29%
Top 10 Hldgs %
40.91%
Holding
1,580
New
569
Increased
340
Reduced
178
Closed
473

Top Buys

Rank Stock Value
1
HTHT icon
Huazhu Hotels Group
HTHT
+$25.7M
2
JD icon
JD.com
JD
+$24.4M
3
MOMO
Hello Group
MOMO
+$23.4M
4
HUYA
Huya Inc
HUYA
+$18.1M
5
EBAY icon
eBay
EBAY
+$5.64M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 28.74%
2 Communication Services 16.3%
3 Technology 12.74%
4 Industrials 8.05%
5 Financials 7.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LIVN icon
826
LivaNova
LIVN
$4.51B
$14K ﹤0.01%
198
+121
+157% +$8.86K
NAVI icon
827
Navient
NAVI
$833M
$14K ﹤0.01%
999
USNA icon
828
Usana Health Sciences
USNA
$420M
$14K ﹤0.01%
+174
New +$13.8K
LCI
829
DELISTED
Lannett Company, Inc.
LCI
$14K ﹤0.01%
+561
New +$14.8K
EPAY
830
DELISTED
Bottomline Technologies Inc
EPAY
$14K ﹤0.01%
+325
New +$15.1K
ACRS icon
831
Aclaris Therapeutics
ACRS
$767M
$13K ﹤0.01%
+5,749
New +$31.3K
AKBA icon
832
Akebia Therapeutics
AKBA
$351M
$13K ﹤0.01%
+2,786
New +$15.8K
AMED
833
DELISTED
Amedisys
AMED
$13K ﹤0.01%
104
-49
-32% -$5.82K
ENTA icon
834
Enanta Pharmaceuticals
ENTA
$373M
$13K ﹤0.01%
150
+141
+1,567% +$12.7K
EQH icon
835
Equitable Holdings
EQH
$13.1B
$13K ﹤0.01%
+613
New +$13.2K
KNSA icon
836
Kiniksa Pharmaceuticals
KNSA
$5.74B
$13K ﹤0.01%
+983
New +$15.3K
MNRO icon
837
Monro
MNRO
$401M
$13K ﹤0.01%
157
-4
-2% -$333
PAHC icon
838
Phibro Animal Health
PAHC
$1.5B
$13K ﹤0.01%
+421
New +$13.2K
WD icon
839
Walker & Dunlop
WD
$1.78B
$13K ﹤0.01%
244
-1,903
-89% -$101K
ARA
840
DELISTED
American Renal Associates Holdings, Inc
ARA
$13K ﹤0.01%
+1,744
New +$11.5K
COST icon
841
Costco
COST
$423B
$12K ﹤0.01%
45
-1,455
-97% -$363K
FRPT icon
842
Freshpet
FRPT
$2.92B
$12K ﹤0.01%
+272
New +$12.3K
IDYA icon
843
IDEAYA Biosciences
IDYA
$3.4B
$12K ﹤0.01%
+1,243
New +$13.5K
INO icon
844
Inovio Pharmaceuticals
INO
$57.4M
$12K ﹤0.01%
+349
New +$13.9K
SIGI icon
845
Selective Insurance
SIGI
$5.68B
$12K ﹤0.01%
159
+145
+1,036% +$10.3K
SUP
846
DELISTED
Superior Industries International
SUP
$12K ﹤0.01%
3,597
+2,135
+146% +$9.81K
VBTX
847
DELISTED
Veritex Holdings
VBTX
$12K ﹤0.01%
+453
New +$11.7K
AMH icon
848
American Homes 4 Rent
AMH
$12.4B
$11K ﹤0.01%
+447
New +$10.7K
AR icon
849
Antero Resources
AR
$11.2B
$11K ﹤0.01%
+1,919
New +$13.8K
BLDR icon
850
Builders FirstSource
BLDR
$7.8B
$11K ﹤0.01%
676
+609
+909% +$9.11K

Similar funds

Point72 Hong Kong's Q2 2019 Portfolio in Review

As of Q2 2019, Point72 Hong Kong held 1,580 positions worth $365M, up 44% from $253M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Point72 Hong Kong deployed $103M of net new capital in Q2 2019, opening 569 new positions and adding to 340 existing holdings. Its largest new stake was Huazhu Hotels Group: 687,619 shares worth $24.9M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, down from 29% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $17M trimmed.

  • Point72 Hong Kong's largest Q2 2019 buy was Huazhu Hotels Group: 687,619 shares worth $24.9M.
  • Point72 Hong Kong added most to JD.com in Q2 2019, an estimated $24.4M increase.
  • Point72 Hong Kong's biggest Q2 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $17M.
  • Point72 Hong Kong fully exited Pinduoduo in Q2 2019, selling an estimated $31.7M.
  • Point72 Hong Kong's ten largest holdings make up 41% of its $365M portfolio in Q2 2019.
  • Point72 Hong Kong opened 569 new positions and closed 473 in Q2 2019.
  • Point72 Hong Kong's portfolio value rose 44% quarter-over-quarter to $365M.

Based on Point72 Hong Kong's 13F filing for Q2 2019, filed 14 Aug 2019.